{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Taking Control of Cancer","title":"Episode 22: Live at the UK Oncology Forum pt2","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/bfdeab14\"></iframe>","width":"100%","height":180,"duration":1613,"description":"In part two of our special from the UK Oncology Forum in Harrogate, Steve Bland is once again joined by Wayne Douglas, Programme Lead for Diagnosis and Treatment at the North East London Cancer Alliance, to talk about a potentially life-saving pilot project between the alliance and Natera, who are a world-leader in cell-free DNA testing with a focus on women’s health, oncology and organ health.\nSteve and Wayne are joined by Dr Francesca Jackson-Spence, Clinical Research fellow in Genitourinary oncology at Bart’s Cancer Institute, Queen Mary University of London, PhD candidate; and Dr Angel A. Rodriguez, MD Oncology and Senior Medical Director at Natera.\nThe project will evaluate the real-world impact in an NHS setting of circulating tumour DNA (ctDNA) testing using Signatera™ to inform follow-on treatment decisions of early stage urothelial and gastro-intestinal cancer patients. Signatera™ is a personalised and highly sensitive tumour-informed cDNA test for molecular residual disease detection (MRD), to inform treatment decisions for cancer patients with solid tumours.\nThis pilot will help better select the patients who need treatments, and de-escalate therapy for those who don’t need it.\nPlease let us know what you think of our podcasts and complete this short feedback form (it will only take five minutes).","thumbnail_url":"https://img.transistorcdn.com/pNSBE06UHjfVWKNkVK7BI5Bn_Oc1g4r5BX9MjTclG-Y/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yMjE0/YjcxZTdkYmZiZTdj/MzZmMGQyYTliMzU1/MTQ3Ni5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}